Malignant Giant Cell Tumor of Bone with a KRAS G12V Mutation

Sara Donigian, Susan L. Whiteway, Sean J. Hipp, Dustin Lybeck, Rebecca O. Clark*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Malignant giant cell tumor of bone (GCTB) is a rare, aggressive, sarcoma occurring in adolescent and young adults. It is characterized by the presence of multinucleated giant cells and an aggressive clinical course. Because of the rarity of this tumor, no standard therapies have been identified. Current treatment regimens often include osteosarcoma chemotherapy protocols. We present a case of a malignant GCTB with a KRAS G12V mutation. This mutation is a known oncogenic driver that has not previously been reported on patients with malignant GCTB.

Original languageEnglish
Pages (from-to)E268-E271
JournalJournal of Pediatric Hematology/Oncology
Volume44
Issue number1
DOIs
StatePublished - 1 Jan 2022

Keywords

  • Bone
  • Giant cell
  • KRAS
  • Sarcoma

Cite this